Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants

被引:170
|
作者
Shi, Xiaoguang [1 ]
Liu, Rengyun [1 ]
Basolo, Fulvio [2 ]
Giannini, Riccardo [2 ]
Shen, Xiaopei [1 ]
Teng, Di [1 ]
Guan, Haixia [3 ,4 ]
Shan, Zhongyan [3 ,4 ]
Teng, Weiping [3 ,4 ]
Musholt, Thomas J. [5 ]
Al-Kuraya, Khawla [6 ]
Fugazzola, Laura [7 ,8 ]
Colombo, Carla [7 ,8 ]
Kebebew, Electron [9 ]
Jarzab, Barbara [10 ]
Czarniecka, Agnieszka [10 ]
Bendlova, Bela [11 ]
Sykorova, Vlasta [11 ]
Sobrinho-Simoes, Manuel [12 ,13 ]
Soares, Paula [12 ,13 ]
Shong, Young Kee [14 ]
Kim, Tae Yong [14 ]
Cheng, Sonia [15 ]
Asa, Sylvia L. [15 ]
Viola, David [16 ]
Elisei, Rossella [16 ]
Yip, Linwah [17 ]
Mian, Caterina [18 ]
Vianello, Federica [19 ]
Wang, Yangang [20 ]
Zhao, Shihua [20 ]
Oler, Gisele [21 ]
Cerutti, Janete M. [21 ]
Puxeddu, Efisio [22 ]
Qu, Shen [23 ]
Wei, Qing
Xu, Huixiong [24 ]
O'Neill, Christine J. [25 ]
Sywak, Mark S. [25 ]
Clifton-Bligh, Roderick [25 ]
Lam, Alfred K. [26 ]
Riesco-Eizaguirre, Garcilaso [27 ,28 ,29 ,30 ]
Santisteban, Pilar [29 ,30 ]
Yu, Hongyu [31 ]
Tallini, Giovanni [32 ]
Holt, Elizabeth H. [33 ]
Vasko, Vasily [34 ]
Xing, Mingzhao [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Endocrinol Diabet & Metab, Lab Cellular & Mol Thyroid Res,Dept Med, Baltimore, MD 21287 USA
[2] Dept Surg, Div Pathol, I-56126 Pisa, Italy
[3] China Med Univ, Hosp 1, Endocrine Inst, Shenyang 110001, Liaoning, Peoples R China
[4] China Med Univ, Hosp 1, Dept Endocrinol & Metab, Liaoning Prov Key Lab Endocrine Dis, Shenyang 110001, Liaoning, Peoples R China
[5] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Endocrine Surg, D-55101 Mainz, Germany
[6] King Faisal Specialist Hosp & Res Ctr, Res Ctr, Human Canc Genom Res, Riyadh 12713, Saudi Arabia
[7] IRCCS Ca Granda Policlin, Fdn Inst Ricovero & Cura Carattere Sci, Milan, Italy
[8] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy
[9] NCI, Endocrine Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[10] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, PL-44101 Gliwice, Poland
[11] Inst Endocrinol, Dept Mol Endocrinol, Prague 11694, Czech Republic
[12] Univ Porto Ipatimup, Inst Mol Pathol & Immunol, P-4200319 Oporto, Portugal
[13] Univ Porto, Fac Med, P-4200319 Oporto, Portugal
[14] Univ Ulsan, Coll Med, Seoul, South Korea
[15] Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2C4, Canada
[16] Univ Pisa, WHO, Endocrine Unit,Dept Clin & Expt Med, Collaborating Ctr Study & Treatment Thyroid Dis &, I-56124 Pisa, Italy
[17] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA
[18] Univ Padua, Endocrinol Unit, Dept Med, I-35128 Padua, Italy
[19] IRCCS, Veneto Inst Oncol, I-35128 Padua, Italy
[20] Qingdao Univ, Affiliated Hosp, Dept Endocrinol, Qingdao 266003, Peoples R China
[21] Univ Fed Sao Paulo, Div Genet, Genet Bases Thyroid Tumor Lab, BR-04039032 Sao Paulo, Brazil
[22] Univ Perugia, Dept Internal Med, I-06100 Perugia, Italy
[23] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Endocrinol,Thyroid Inst, Shanghai 200072, Peoples R China
[24] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Med Ultrasound,Thyroid Inst, Shanghai 200072, Peoples R China
[25] Univ Sydney, Endocrine Surg Unit, Sydney, NSW 2052, Australia
[26] Griffith Univ Gold Coast, Canc Mol Pathol Menzies Hlth Inst Queensland, Southport, Qld 4215, Australia
[27] Hosp La Paz, Hlth Res Inst, Madrid 28029, Spain
[28] Hosp Univ Mostoles, Madrid 28029, Spain
[29] CSIC, Spanish Council Res, Biomed Res Inst, Alberto Sols, Madrid 28029, Spain
[30] Autonomous Univ Madrid, Madrid 28029, Spain
[31] Second Mil Med Univ, Changzheng Hosp, Dept Pathol, Shanghai 200003, Peoples R China
[32] Univ Bologna, Osped Bellaria, Anat Pathol Unit, Dept Med, I-40139 Bologna, Italy
[33] Yale Univ, Sch Med, Dept Internal Med, Endocrine Sect, New Haven, CT 06520 USA
[34] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA
来源
基金
巴西圣保罗研究基金会; 美国国家卫生研究院;
关键词
BRAF V600E MUTATION; TALL-CELL VARIANT; NEEDLE-ASPIRATION BIOPSY; FOLLICULAR VARIANT; BRAF(V600E) MUTATION; SURGICAL-TREATMENT; CLINICAL-FEATURES; CARCINOMA; ASSOCIATION; RECURRENCE;
D O I
10.1210/jc.2015-2917
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive data demonstrating differential risks of PTC variants to support. Objective: This study sought to establish the differential clinicopathological risk of major PTC variants: conventional PTC (CPTC), follicular-variant PTC (FVPTC), and tall-cell PTC (TCPTC). Methods: This was a retrospective study of clinicopathological outcomes of 6282 PTC patients (4799 females and 1483 males) from 26 centers and The Cancer Genome Atlas in 14 countries with a median age of 44 years (interquartile range, 33-56 y) and median follow-up time of 37 months (interquartile range, 15-82 mo). Results: The cohort consisted of 4702 (74.8%) patients with CPTC, 1126 (17.9%) with FVPTC, and 239 (3.8%) with TCPTC. The prevalence of high-risk parameters was significantly different among the three variants, including extrathyroidal invasion, lymph node metastasis, stages III/IV, disease recurrence, mortality, and the use (need) of radioiodine treatment (all P < .001), being highest in TCPTC, lowest in FVPTC, and intermediate in CPTC, following an order of TCPTC > CPTC >> FVPTC. Recurrence and mortality in TCPTC, CPTC, and FVPTC were 27.3 and 6.7%, 16.1 and 2.5%, and 9.1 and 0.6%, corresponding to events per 1000 person-years (95% confidence interval [CI]) of 92.47 (64.66-132.26) and 24.61 (12.31-49.21), 34.46 (30.71-38.66), and 5.87 (4.37-7.88), and 24.73 (18.34-33.35) and 1.68 (0.54-5.21), respectively. Mortality hazard ratios of CPTC and TCPTC over FVPTC were 3.44 (95% CI, 1.07-11.11) and 14.96 (95% CI, 3.93-56.89), respectively. Kaplan-Meier survival analyses showed the best prognosis in FVPTC, worst in TCPTC, and intermediate in CPTC in disease recurrence-free probability and disease-specific patient survival. This was particularly the case in patients at least 45 years old. Conclusion: This large multicenter study demonstrates differential prognostic risks of the three major PTC variants and establishes a unique risk order of TCPTC > CPTC >> FVPTC, providing important clinical implications for specific variant-based management of PTC.
引用
收藏
页码:263 / 273
页数:11
相关论文
共 50 条
  • [1] Impact of sex on the clinicopathological characteristics and prognosis of papillary thyroid cancer
    Yorke, Ekua
    Melck, Adrienne
    Wiseman, Sam M.
    CANADIAN JOURNAL OF SURGERY, 2016, 59 (04) : 287 - 288
  • [2] Impact of telomere length for risk assessment and prognosis in papillary thyroid cancer depending on the clinicopathological features
    Materah Salem Alwehaidah
    Rana Al-Awadhi
    Moody AlRoomy
    Tahani Al Baqer
    Molecular Genetics and Genomics, 2025, 300 (1)
  • [3] Association between pathological variants of papillary thyroid cancer and prognosis
    Iribarren B, Osvaldo
    Madariaga G, Juan
    Zaffiri M, Vitorio
    Huidobro M, Patricio
    Mertens P, Maximiliano
    Iribarren R, Gabriel
    REVISTA CHILENA DE CIRUGIA, 2010, 62 (03): : 228 - 233
  • [4] Differential microRNA expression for diagnosis and prognosis of papillary thyroid cancer
    Ruiz-Pozo, Viviana A.
    Cadena-Ullauri, Santiago
    Guevara-Ramirez, Patricia
    Paz-Cruz, Elius
    Tamayo-Trujillo, Rafael
    Zambrano, Ana Karina
    FRONTIERS IN MEDICINE, 2023, 10
  • [5] Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases
    Zhi, Jingtai
    Zhao, Jingzhu
    Gao, Ming
    Pan, Yi
    Wu, Jianghua
    Li, Yigong
    Li, Dapeng
    Yu, Yang
    Zheng, Xiangqian
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (01) : 59 - 65
  • [6] Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases
    Jingtai Zhi
    Jingzhu Zhao
    Ming Gao
    Yi Pan
    Jianghua Wu
    Yigong Li
    Dapeng Li
    Yang Yu
    Xiangqian Zheng
    International Journal of Clinical Oncology, 2018, 23 : 59 - 65
  • [7] Histological Variants of Papillary Thyroid Cancer in Relation to Clinical and Morphological Parameters and Prognosis
    A. A. Ivanov
    M. A. Bakarev
    E. L. Lushnikova
    Bulletin of Experimental Biology and Medicine, 2023, 174 : 647 - 652
  • [8] Clinicopathological features and prognosis of papillary thyroid cancer patients with type 2 diabetes mellitus
    Shi, Ping
    Zhang, Lan
    Liu, Yan
    Yang, Fei
    Fu, Kai
    Li, Ruicong
    Shi, Huijing
    Wu, Yanzhao
    GLAND SURGERY, 2022, 11 (02) : 358 - 368
  • [9] Histological Variants of Papillary Thyroid Cancer in Relation to Clinical and Morphological Parameters and Prognosis
    Ivanov, A. A.
    Bakarev, M. A.
    Lushnikova, E. L.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2023, 174 (05) : 647 - 652
  • [10] Clinicopathological features of recurrent papillary thyroid cancer
    Jian Zhu
    Xinli Wang
    Xiaoxuan Zhang
    Peifeng Li
    Haifeng Hou
    Diagnostic Pathology, 10